Cambrex Corp., a manufacturer of small molecule innovator and generic APIs, has completed an expansion of its large-scale production capacity at its Charles City, IA plant. The investment included the installation of 1,000 and 4,000 gallon glass lined reactors and additional equipment.
 
The new reactors have been installed in the 7,500 sq.-ft., multi-purpose, manufacturing facility, bringing the cGMP reactor capacity to 23,000 gallons, and the total capacity at the Charles City facility to approximately 107,000 gallons.
 
“Cambrex continues to experience strong demand for large scale small molecule API manufacturing” commented Shawn Cavanagh, chief operating officer of Cambrex. “Charles City is a key strategic site within our global manufacturing network and this additional capacity enables us to take on new customer projects, as well as offering the flexibility for projects to be transferred in from other Cambrex sites as needed.” 
 
This latest expansion follows the construction of a $24M, 4,500 sq.-ft. highly potent API (HPAPI) manufacturing facility at the Charles City facility, scheduled to open in 2019.